Mongolia Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Mongolia

2. **Grant number(s):** 1518-MNG-25b-X / 15-MNG-08h-Y

3. **Date of Decision Letter:** 13 December 2017

4. **Date of the Partnership Framework Agreement:** 11 June 2014

5. **Programme title:** NVS, IPV routine

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine:** Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. **Programme duration:** 2015 – 2018

9. **Indicative Programme Budget:** (subject to the terms of the Partnership Framework Agreement)
   
   Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th>2015-2017</th>
<th>2018</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Programme (US$)</td>
<td>11,153(^1)</td>
<td>184,000</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant / Product switch grant:** a VIG of US$ 100,000 was disbursed on 10 Dec 2015.

11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)\(^5\)

<table>
<thead>
<tr>
<th>Number of vaccines to be purchased with Gavi funds</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV Routine Programme (doses)</td>
<td>95,000</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>184,000</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF.

13. **Self-procurement:** Not applicable.

14. **Co-financing obligations:** Not applicable, as Gavi’s usual co-financing requirements do not apply to IPV.

---

\(^1\) Please refer to section 18 for additional information on IPV presentation.

\(^2\) This is the entire duration of the Programme.

\(^3\) This is the total amount endorsed by Gavi for 2015 to 2018.

\(^4\) This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

\(^5\) This is the amount that Gavi has approved.
15. **Operational support for catch-up campaigns:** Not applicable

16. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>15 May 2018</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial clarifications:** Not applicable

18. **Other conditions**

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Mongolia envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Mongolia.

Signed by,
**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
13 December 2017